Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MR-107A-02 · MR-107A

Other · developed by Viatris Specialty LLC

Phase 3 Most advanced trial (none active)
VTRS Developer
1 Registered trials

What is MR-107A-02?

MR-107A-02 (also coded MR-107A) is a investigational agent studied in acute pain and postoperative pain.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MR-107A
Drug type
Other
Developer
Viatris Specialty LLC (VTRS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06215859 Phase 3 Acute Pain Completed VTRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute PainPainPost Operative Pain

More from Viatris Specialty LLC

Follow VTRS, the company behind MR-107A-02

See VTRS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VTRS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.